BMO Capital Reiterates Outperform Rating on Pfizer (PFE)

October 13, 2025 9:35 AM UTC Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $30.00 price target on Pfizer (NYSE: PFE).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login